Captrust Financial Advisors Reata Pharmaceuticals Inc Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $993,814 - $1.32 Million	12,545 New	12,545 $1.28 Million
Q2 2022 Aug 16, 2022	SELL	$20.71 - $36.5 $4,266 - $7,519	-206 Reduced 88.41%	27 $1,000
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $4,992 - $8,197	207 Added 796.15%	233 $8,000
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $2,663 - $11,539	-104 Reduced 80.0%	26 $1,000
Q3 2021 Nov 16, 2021	SELL	$100.0 - $143.02 $3,000 - $4,290	-30 Reduced 18.75%	130 $13,000
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $9,940 - $19,213	127 Added 384.85%	160 $23,000
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $3,110 - $4,382	33 New	33 $3,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.